Replies to post #139648 on Biotech Values

[turtlepower]

Yes. I was clearly careless in skimming through most of the article even though one of the lines i quoted also indicated he was only considering cancer drugs. However my point still holds. IMO the marketcap is indicative of how valuable the drug is to the company and a 300 M limit cannot be used to predict whether a trial would be successful. Consider CRIS which was less than 200M before the BCC results. Even EXEL may not have had a 300M MC before the MTC results if the market hadn't known that cabo was active in PC.